---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294724853.md"
description: "Supernus Pharma shares trading higher after the company reported better-than-expected Q2 financial results. The company also announced a merger with Indivior Pharma to create diversified, CNS biopharmaceutical company."
datetime: "2026-08-03T17:55:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294724853.md)
  - [en](https://longbridge.com/en/news/294724853.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294724853.md)
generator: "portal-rs"
---

# 

Supernus Pharma shares trading higher after the company reported better-than-expected Q2 financial results. The company also announced a merger with Indivior Pharma to create diversified, CNS biopharmaceutical company.

### Related Stocks

- [SUPN.US](https://longbridge.com/en/quote/SUPN.US.md)
- [INDV.US](https://longbridge.com/en/quote/INDV.US.md)

## Related News & Research

- [Supernus, Indivior agree all-stock merger, combined firm to trade as Supernus on Nasdaq](https://longbridge.com/en/news/294678697.md)
- [Indivior Q2 2026 Earnings Call: Complete Transcript](https://longbridge.com/en/news/296085674.md)
- [Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts](https://longbridge.com/en/news/277467334.md)
- [Supernus Q2 FY26 net loss widens to $58.4 million; revenue rises 32% to $219.1 million](https://longbridge.com/en/news/294679432.md)
- [INDV: Merger forms a $2.2B CNS biopharma leader with strong growth, profitability, and synergies](https://longbridge.com/en/news/294694154.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**